Oncolytic viruses: Overcoming hurdles in scaling and commercialisation

Kai Lipinski, PhD, chief scientific officer of Vibalogics, a Recipharm company, focuses on oncolytic viruses (OVs); explaining how early-stage drug developers can overcome the challenges in scaling up and commercialising their products.